PCSK9 Inhibition: Current Concepts and Lessons from Human Genetics

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Current Atherosclerosis Reports

• Publication date

  2015-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s11883-015-0487-8PMID 25637042
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial.

  2015cited by this paper
• PCSK9 inhibition in LDL cholesterol reduction: genetics and therapeutic implications of very low plasma lipoprotein levels.

  2015cited by this paper
• Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia: 52-Week Results From the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) Randomized Trial

  2014cited by this paper
• Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials.

  2014cited by this paper
• Efficacy and Safety of Alirocumab as Add‐on Therapy in High–Cardiovascular‐Risk Patients With Hypercholesterolemia Not Adequately Controlled With Atorvastatin (20 or 40 mg) or Rosuvastatin (10 or 20 mg): Design and Rationale of the ODYSSEY OPTIONS Studies

  2014cited by this paper
• Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies

  2014cited by this paper
• Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial.

  2014cited by this paper
• Reprint: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults.

  2014cited by this paper
• Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study.

  2014cited by this paper
• 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

  2014cited by this paper
• Efficacy and safety of alirocumab, a fully human PCSK9 monoclonal antibody, in high cardiovascular risk patients with poorly controlled hypercholesterolemia on maximally tolerated doses of statins: rationale and design of the ODYSSEY COMBO I and II trials

  2014cited by this paper
• PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells

  2014cited by this paper
• Living the PCSK9 Adventure: from the Identification of a New Gene in Familial Hypercholesterolemia Towards a Potential New Class of Anticholesterol Drugs

  2014cited by this paper
• Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

  2014cited by this paper
• The severe hypercholesterolemia phenotype: clinical diagnosis, management, and emerging therapies.

  2014cited by this paper
• A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.

  2014cited by this paper
• Design and Rationale of the GAUSS‐2 Study Trial: A Double‐Blind, Ezetimibe‐Controlled Phase 3 Study of the Efficacy and Tolerability of Evolocumab (AMG 145) in Subjects With Hypercholesterolemia Who Are Intolerant of Statin Therapy

  2014cited by this paper
• PCSK9: From discovery to therapeutic applications.

  2014cited by this paper
• Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials.

  2014cited by this paper
• Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab.

  2014cited by this paper
• Risk factor control for coronary artery disease secondary prevention in large randomized trials.

  2013cited by this paper
• Statins: new American guidelines for prevention of cardiovascular disease.

  2013cited by this paper
• Effect of the Proprotein Convertase Subtilisin/Kexin 9 Monoclonal Antibody, AMG 145, in Homozygous Familial Hypercholesterolemia

  2013cited by this paper
• New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

  2013cited by this paper
• Residual dyslipidemia among United States adults treated with lipid modifying therapy (data from National Health and Nutrition Examination Survey 2009-2010).

  2013cited by this paper
• Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics

  2013cited by this paper
• [Effect of a monoclonal antibody to PCSK9 on LDL cholesterol].

  2012cited by this paper
• Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

  2012cited by this paper
• Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia: The Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterole

  2012cited by this paper
• Effect of a monoclonal antibody to PCSK9 on LDL cholesterol.

  2012cited by this paper
• Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia.

  2012cited by this paper
• Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.

  2012cited by this paper
• Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study.

  2012cited by this paper
• Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.

  2012cited by this paper
• The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

  2012cited by this paper
• Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study.

  2012cited by this paper
• Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey.

  2011cited by this paper
• Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.

  2011cited by this paper
• Evidence-Based Management of Statin Myopathy

  2010cited by this paper
• Lipoprotein(a) as a cardiovascular risk factor: current status

  2010cited by this paper
• Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.

  2010cited by this paper
• Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

  2010cited by this paper
• PCSK9 Dominant Negative Mutant Results in Increased LDL Catabolic Rate and Familial Hypobetalipoproteinemia

  2009cited by this paper
• A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates

  2009cited by this paper
• Genetic variants associated with Lp(a) lipoprotein level and coronary disease.

  2009cited by this paper
• Genetically elevated lipoprotein(a) and increased risk of myocardial infarction.

  2009cited by this paper
• Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels

  2009cited by this paper
• Three-year follow-up and event rates in the international REduction of Atherothrombosis for Continued Health Registry

  2009cited by this paper
• Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries.

  2009cited by this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cited by this paper
• The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis

  2007cited by this paper
• Secreted PCSK9 downregulates low density lipoprotein receptor through receptor-mediated endocytosis Published, JLR Papers in Press, April 20, 2007.

  2007cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins

  2007cited by this paper
• LDL-C goal Attainment Among Patients Newly Diagnosed With Coronary Heart Disease or Diabetes in a Commercial HMO

  2007cited by this paper
• Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation*

  2007cited by this paper
• Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy.

  2006cited by this paper
• Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.

  2006cited by this paper
• Abstract 340: The C679X Mutation in PCSK9 is Present and Lowers Blood Cholesterol in a Southern African Population

  2006cited by this paper
• Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote.

  2006cited by this paper
• Contemporary management of dyslipidemia in high-risk patients: targets still not met.

  2006cited by this paper
• Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9

  2005cited by this paper
• Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins.

  2005cited by this paper
• Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.

  2005cited by this paper
• Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study

  2005cited by this paper
• Intensive versus moderate lipid lowering with statins after acute coronary syndromes.

  2004influential reference
• Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.

  2004cited by this paper
• Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

  2003cited by this paper
• Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity.

  2000cited by this paper
• Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations.

  1991cited by this paper
• Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

  1986cited by this paper

• Achieving the Vision of Genomics to Improve Health for All Requires a Focus on Diversity, Equity, and Inclusion

  2025cites this paper
• Intravenous injection of PCSK9 gain-of-function mutation in C57BL/6J background mice on Angiotensin II-induced AAA.

  2025cites this paper
• Achieving the vision of genomics to improve health for all requires a focus on diversity, equity and inclusion

  2025cites this paper
• Associations of pro-protein convertase subtilisin-like kexin type 9, soluble low-density lipoprotein receptor and coronary artery disease: A case-control study.

  2022cites this paper
• MiR-337-3p lowers serum LDL-C level through targeting PCSK9 in hyperlipidemic mice.

  2021cites this paper
• Prevalence of Cardiovascular Risk Factors and Heterozygous Familial Hypercholesterolemia in Premature Atherosclerotic Patients Presenting with Acute Coronary Syndrome

  2021cites this paper
• Coronary Artery Disease and Myocardial Infarction

  2017cites this paper
• ANMCO/ISS/AMD/ANCE/ARCA/FADOI/GICR-IACPR/SICI-GISE/SIBioC/SIC/SICOA/SID/SIF/SIMEU/SIMG/SIMI/SISA Joint Consensus Document on cholesterol and cardiovascular risk: diagnostic–therapeutic pathway in Italy

  2017cites this paper
• The role of registries and genetic databases in familial hypercholesterolemia.

  2017cites this paper
• Genetics for the Identification of Lipid Targets Beyond PCSK9.

  2017cites this paper
• PCSK9 inhibitors in the current management of atherosclerosis.

  2017cites this paper
• Genetics: Implications for Prevention and Management of Coronary Artery Disease.

  2016cites this paper
• Importance of early recognition of heterozygous familial hypercholesterolaemia

  2015influential citation
• Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults

  2015influential citation
• Dyslipidaemia, diet and drugs

  2015cites this paper
• Rationale and design of the familial hypercholesterolemia foundation CAscade SCreening for Awareness and DEtection of Familial Hypercholesterolemia registry.

  2014cites this paper